Oncodesign and LNGT: research collaboration for advancing drug discovery efforts with Ipsen in Parkinson's disease
Oncodesign and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the department of neurosciences at the KU Leuven, an academic group exploring the roles of LRRK2 and a-synuclein in Parkinson’s disease headed by Professor Veerle Baekelandt, announced that they have entered into a research collaboration to evaluate, with Ipsen, Oncodesign’s compounds in multiple pharmacology models for Parkinson's disease. The collaboration builds on Oncodesign's LRRK2 program with advanced Nanocyclix(R) lead molecules that was partnered with Ipsen in January 2012.
“This collaboration with Oncodesign is a perfect example of translational research in action,” said Veerle Baekelandt, Ph.D., principle investigator of LNGT. “Parkinson’s disease has been the focus of our research for more than ten years now. We are very pleased that Oncodesign has selected our lab as a partner for advancing their kinase program,” she added.
Under the terms of the agreement, Oncodesign and LNGT will closely collaborate to advance Oncodesign's Parkinson’s disease program towards clinical development. LNGT will receive full financial support from Oncodesign for these activities.
Other news from the department research and development
